drugset / Trial / NCT01012479

Efficacy and Safety of Candesartan Cilexetil Plus Hydrochlorothiazide in Subjects With Severe Hypertension

NCT01012479

Phase 4 Completed 107 enrolled Takeda
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to see if Candesartan, once daily (QD), added with Hydrochlorothiazide may be helpful in treating people with newly diagnosed severe essential hypertension.

Timeline

Start
2009-10
Primary completion
2010-05
Completion
2010-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Candesartan cilexetil Unknown 32 mg Oral
Subject Hydrochlorothiazide Unknown 25 mg Oral